Beacon Pharmaceuticals Limited, the leading oncology company in Bangladesh, has introduced a groundbreaking treatment for lung cancer: Tagrix, the first global generic version of osimertinib.
Learn more
Beacon is acknowledged as the forefront developer and producer of life-saving oncological, biotech, and general products; locally and globally. With an impressive portfolio of over 250 generic drugs and 68 oncology products, we consistently bring 15 to 20 new high-tech products to market each year.
Our achievements are a direct result of the remarkable strength of our R&D team and our ongoing commitment to investment in investigation and exploration. This dedication has allowed us to consistently innovate, pushing the boundaries of what is possible in the pharmaceutical industry.
The synergy between our research and development initiatives and the evolving market needs, propelled by technological advancements, is truly inspiring. It reflects our adaptability and foresight in meeting the dynamic demands of the industry. The establishment of a state-of-the-art research lab is a testament to our unwavering dedication to innovation. This investment not only amplifies our technological capabilities but also positions us strategically to create distinctive market opportunities.
Our specialised R&D team holds impeccable skills & expertise in advancing and formulating complex generic products. They are committed to innovation and differentiation. The successful development of multi-layer tablets, sustained release formulations, dispersible tablets, prefilled syringes & lyophilized injectables reflects their unwavering commitment to excellence.